Overview checkpoint inhibitors
Starting from 2010’s, immunotherapy has brought a revolution of changes in how cancers are treated. Using the immune system to target tumors, largely by suppressing the programmed cell death protein (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) pathways, has been effective for melanoma, non-small cell lung cancer, renal cell carcinoma, etc. A comprehensive review of known immune checkpoint inhibitors (ICI) could be found in a 2017 Nature review. https://www.nature.com/articles/nrclinonc.2017.88
